E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

• Status: Completed
• Trial end date: 2014-11-01

Summary

Primary:

• Phase Ib: To define the safety, tolerability and maximum tolerated dose (MTD) of lenvatinib administered in combination with dacarbazine.

• Phase II: To evaluate the safety and tolerability of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.

Secondary:

-Phase II: To make a preliminary assessment of the efficacy of lenvatinib administered in combination with dacarbazine, compared with dacarbazine alone.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Eisai Inc.
• Collaborator: Quintiles, Inc.
• Treatments: Dacarbazine; Lenvatinib